608 related articles for article (PubMed ID: 34108285)
1. Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays.
Yun S; Ryu JH; Jang JH; Bae H; Yoo SH; Choi AR; Jo SJ; Lim J; Lee J; Ryu H; Cho SY; Lee DG; Lee J; Kim SC; Park YJ; Lee H; Oh EJ
Ann Lab Med; 2021 Nov; 41(6):577-587. PubMed ID: 34108285
[TBL] [Abstract][Full Text] [Related]
2. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs.
Van Elslande J; Decru B; Jonckheere S; Van Wijngaerden E; Houben E; Vandecandelaere P; Indevuyst C; Depypere M; Desmet S; André E; Van Ranst M; Lagrou K; Vermeersch P
Clin Microbiol Infect; 2020 Nov; 26(11):1557.e1-1557.e7. PubMed ID: 32745595
[TBL] [Abstract][Full Text] [Related]
3. Clinical diagnostic performance evaluation of five immunoassays for antibodies to SARS-CoV-2 diagnosis in a real-life routine care setting.
Akyala AI; Awayimbo JR; Ogo AC; Chima NJ; Billyrose OMA; Engom AOG
Pan Afr Med J; 2021; 39():3. PubMed ID: 34178231
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
[TBL] [Abstract][Full Text] [Related]
5. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech).
Nicol T; Lefeuvre C; Serri O; Pivert A; Joubaud F; Dubée V; Kouatchet A; Ducancelle A; Lunel-Fabiani F; Le Guillou-Guillemette H
J Clin Virol; 2020 Aug; 129():104511. PubMed ID: 32593133
[TBL] [Abstract][Full Text] [Related]
6. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management.
Speletas M; Kyritsi MA; Vontas A; Theodoridou A; Chrysanthidis T; Hatzianastasiou S; Petinaki E; Hadjichristodoulou C
Front Immunol; 2020; 11():609242. PubMed ID: 33424863
[TBL] [Abstract][Full Text] [Related]
8. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
Al-Mughales JA; Al-Mughales TJ; Saadah OI
Front Immunol; 2021; 12():705441. PubMed ID: 34539635
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of ELISA Using Total Antibody against Plant-Expressed Recombinant Nucleocapsid Protein of SARS-CoV-2.
Tariq M; Hur J; Seo JW; Kim DY; Yun NR; Lee YM; Bang MS; Hwang SY; Kim CM; Lee JH; Song KH; Lee H; Jung J; Park JY; Kim HB; Kim ES; Lee S; Kim DM
Microbiol Spectr; 2021 Dec; 9(3):e0067221. PubMed ID: 34817278
[TBL] [Abstract][Full Text] [Related]
10. A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
Egorov AI; Griffin SM; Fuzawa M; Kobylanski J; Grindstaff R; Padgett W; Simmons S; Hallinger DR; Styles JN; Wickersham L; Sams E; Hudgens E; Wade TJ
Microbiol Spectr; 2021 Oct; 9(2):e0069321. PubMed ID: 34523986
[TBL] [Abstract][Full Text] [Related]
11. Multicenter evaluation of four immunoassays for the performance of early diagnosis of COVID-19 and assessment of antibody responses of patients with pneumonia in Taiwan.
Lin YC; Lee YL; Cheng CY; Tseng WP; Wu JL; Lin CH; Chung MY; Kang CM; Lee YF; Chen CP; Huang CH; Liu CE; Cheng SH; Chen SC; Chen SY; Hsueh PR
J Microbiol Immunol Infect; 2021 Oct; 54(5):816-829. PubMed ID: 33676864
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies.
Gutiérrez-Cobos A; Gómez de Frutos S; Domingo García D; Navarro Lara E; Yarci Carrión A; Fontán García-Rodrigo L; Fraile Torres AM; Cardeñoso Domingo L
Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):955-961. PubMed ID: 33236268
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of commercial automated SARS-CoV-2 immunoassays.
Kittel M; Muth MC; Zahn I; Roth HJ; Thiaucourt M; Gerhards C; Haselmann V; Neumaier M; Findeisen P
Int J Infect Dis; 2021 Feb; 103():590-596. PubMed ID: 33310108
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid Antibodies.
Hubbard JA; Geno KA; Khan J; Szczepiorkowski ZM; de Gijsel D; Ovalle AA; AlSalman AS; Gallagher TL; Johnston AA; Tibbetts AR; Vital SE; Cervinski MA; Nerenz RD
J Appl Lab Med; 2021 Mar; 6(2):429-440. PubMed ID: 32976593
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity.
Lee N; Jeong S; Park MJ; Song W
PLoS One; 2021; 16(6):e0253889. PubMed ID: 34185813
[TBL] [Abstract][Full Text] [Related]
16. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
[TBL] [Abstract][Full Text] [Related]
17. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
[TBL] [Abstract][Full Text] [Related]
18. Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan.
Chen SY; Lee YL; Lin YC; Lee NY; Liao CH; Hung YP; Lu MC; Wu JL; Tseng WP; Lin CH; Chung MY; Kang CM; Lee YF; Lee TF; Cheng CY; Chen CP; Huang CH; Liu CE; Cheng SH; Ko WC; Hsueh PR; Chen SC
Emerg Microbes Infect; 2020 Dec; 9(1):2157-2168. PubMed ID: 32940547
[TBL] [Abstract][Full Text] [Related]
19. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
[TBL] [Abstract][Full Text] [Related]
20. Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera.
Valdivia A; Torres I; Latorre V; Francés-Gómez C; Ferrer J; Forqué L; Costa R; de la Asunción CS; Huntley D; Gozalbo-Rovira R; Buesa J; Giménez E; Rodríguez-Díaz J; Geller R; Navarro D
J Med Virol; 2021 Apr; 93(4):2301-2306. PubMed ID: 33236799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
